| Japanese |
|---|
| Title | 111In-標識抗ミオシンモノクローナル抗体-F abイメージングの臨床応用 (第1報) - 体内挙動と撮像時期の検討 - |
|---|
| Subtitle | ≪原著≫ |
|---|
| Authors | 玉木長良*, 山田武彦**, 松森昭**, 藤田透*, 渡辺祐司*, 米倉義晴*, 遠藤啓吾*, 小西淳二*, 河合忠一* |
|---|
| Authors(kana) | |
|---|
| Organization | *京都大学医学部放射線核医学科, **第三内科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 26 |
|---|
| Number | 6 |
|---|
| Page | 715-722 |
|---|
| Year/Month | 1989/6 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」心疾患20例に111In-抗ミオシンモノクローナル抗体-F ab 74 MBq (2 mCi)を静注し, その安全性と体内挙動および撮像時期について検討した. いずれの例にも本剤に起因すると考えられる副作用は認められず, 皮内テストも陰性であり, その安全性が確認された. 被曝線量は腎臓で3.6 rad, 全身で0.36 radであり, 許容範囲内であった. 血中消失曲線は二相性で, T 1/2はおのおの6.3時間, 25.8時間であり, 24時間後に21%, 48時間後に11%残存した. 尿中排泄はおのおの30%, 37%であった. 本剤投与24時間後に撮像した4例は, いずれも心内腔の放射能が高く, 障害心筋部への異常集積の有無の判定が困難であったが, 48時間後にはほとんどの例で判定可能であった. ただし2例は48時間後にも心内腔の放射能が高く, 72時間後の撮像が必要となった. そのうち1例では, 48時間後に施行したSPECTが心内腔の放射能の残存と心筋への異常集積との鑑別に役立った. 本剤は障害心筋を陽性描出する優れた方法であるが, 血中消失が遅いため, 48時間後の撮像が必要であり, SPECTの併用も役立つと考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 111In-antimyosin, Myocardial infarction, Myocarditis, Tracer kinetics. |
|---|
| English |
|---|
| Title | Clinical Trial of 111In-Antimyosin Antibody Imaging : (1) Assessment of Tracer Kinetics and Imaging Time |
|---|
| Subtitle | - Original Articles - |
|---|
| Authors | Nagara TAMAKI*, Takehiko YAMADA**, Akira MATSUMORI**, Toru FUJITA*, Yuji WATANABE*, Yoshiharu YONEKURA*, Keigo ENDO*, Junji KONISHI*, Chuichi KAWAI** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Nuclear Medicine, **The Third Division, Department of Internal Medicine, Faculty of Medicine Kyoto University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 26 |
|---|
| Number | 6 |
|---|
| Page | 715-722 |
|---|
| Year/Month | 1989/6 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] The human clinical trial of 111In-antimyosin antibody was performed in 20 patients with various cardiac disorders to assess its safety and tracer kinetics and to determine the optimal imaging time. There were no side effects derived from this tracer after its administration. The skin test and the antimurine antibody were both negative in any patient. The radiation dose to the kidney (3.6 rad) and to the whole body (0.36 rad) was acceptable. The half life of the blood clearance was 6.3 hours (fast component) and 25.8 hours (slow component) with the relatively high retention of blood activity at 24 hours (21%) and at 48 hours (11%). The planar images at 24 hours after the tracer administration in 4 patients showed high residual blood-pool activity without delineating significant myocardial uptake, while the images at 48 hours clearly demonstrated the presence or absence of discrete myocardial uptake. However ,2 patients showed significant residual blood-pool activity at 48 hours after the injection which needed 72 hour delayed scan in order to identify the myocardial uptake. In one patient, the single-photon tomography (SPECT) was useful to delineate the myocardial uptake from the residual blood-pool activity at 48 hours after the injection. Although this tracer provides an elegant technique for identifying myocardial necrosis, it needs 48 hours delayed scan and/or SPECT imaging because of relatively slow blood clearance. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 111In-antimyosin, Myocardial infarction, Myocarditis, Tracer kinetics. |
|---|